Great thoughts! So where we thought Dr. Missling was leveraging the Rett Syndrome data and PDD data for AD approval (ob, and throw in Fragile X and one other rare disease data next year), he may be leveraging all three for the prophylactic approval instead. A longer “long” game indeed! And to think some here think he doesnt know the difference between midyear and 1 half. He’s not as think as you dumb he is, lol.
I believe in order to understand while others are so proud they need to fully understand in order to believe!
Market Data 
Markets 
AI
